论文部分内容阅读
为探讨静脉溶栓治疗急性心肌梗塞的疗效,用蝮蛇抗栓酶(VAE)、小剂量尿激酶(LUK)、大剂量尿激酶(HUK)静脉注射治疗急性心肌梗塞各51例、33例及51例进行疗效比较。冠脉再通率分别为39.22%(20/51)、45.45%(15/33)与60.08%(31/51)(每两组相比P均<0.01);5周病死率分别为9.80%(5/51)、9.09%(3/33)与7.84%(4/51)(P<0.01);出血率分别为13.72%(7/51)、12.12%(4/33)与13.72%(7/51)(P>0.05);QRS记分分别为3.12±0.42、2.98±0.40与2.79±0.39;CK峰值分别为248.73±31.22U、216.6±25.67U与219.68±23.16U。HUK组疗效明显优于VAE和LUK组。推荐UK的适宜用量为150万U30分钟内静脉滴入。
To investigate the curative effect of intravenous thrombolysis on acute myocardial infarction, 51 cases of acute myocardial infarction (MI), 33 cases of acute myocardial infarction (AMI) were treated with intravenous injection of high dose urokinase (HUK) 51 cases were compared. The rates of coronary recanalization were 39.22% (20/51), 45.45% (15/33) and 60.08% (31/51) respectively (P <0.01 for each group). The 5-week mortality rates were 9.80% (5/51), 9.09% (3/33) and 7.84% (4/51) respectively (P <0.01). The bleeding rates were 13.72 (7/51), 12.12% (4/33) and 13.72% (7/51) respectively (P> 0.05). The QRS scores were 3.12 ± 0.42 and 2.98 ± 0.40 and 2.79 ± 0.39 respectively; CK peaks were 248.73 ± 31.22U, 216.6 ± 25.67U and 219.68 ± 23.16U, respectively. HUK group was significantly better than VAE and LUK group. Recommended the appropriate amount of UK 1.5 million U30 intravenous infusion within 30 minutes.